Citi analyst Joel Beatty initiated Amarin with a Buy rating and $5 price target. The biopharmaceutical company closed yesterday up 1c to $3.00. If the ongoing REDUCE-IT outcomes trial for the company's sole drug Vascepa is positive in late 2017 or early 2018, the label will be expanded to treat adults with triglycerides greater than or equal to 150, which is almost a 20 times larger market than the drug's current indication, Beatty tells investors in a research note. The analyst estimates the stock would trade up to $16 per share on news of a positive trial. In this scenario, he models Vascepa sales peaking at $2.6B in 2024.